Ovarian cancer is the second most common gynecologic malignancy, the most common cause of gynecologic cancer death, and the fifth leading cause of cancer death in women in developed countries.
INTRODUCTION
Ovarian cancer is the second most common gynecologic malignancy, the most common cause of gynecologic cancer death, and the fifth leading cause of cancer death in women in developed countries. 1 In India, ovarian cancer is the third leading site of cancer among women, trailing behind cervix and breast cancer. Each year, over 22,000 women are diagnosed worldwide with epithelial ovarian cancer and 15,000 die of it. 2 In patients with cancers of the breast and endometrium, the relationship between tumor estrogen and progesterone receptor (PR) expression and prognosis is well documented. Estrogen is considered a primary culprit in the development of ovarian cancer as 70% of ovarian cancers express estrogen receptors (ERs), whereas progesterone and its receptors are protective against ovarian cancer. 3, 4 However, the clinical significance of ER and PR content in ovarian carcinomas has not been well established due to conflicting data from only a few immunohistochemical studies available in the literature.
The present study was taken up to understand the disease morbidity and to know the role of steroid receptors in the pathogenesis of ovarian cancers.
The main aims and objectives was to study the various clinicopathological parameters in ovarian cancer and to evaluate the expression of estrogen and progesterone receptors and Her2/neu in patients with ovarian cancer and to correlate the results of immunohistochemistry with various clinicopathological parameters.
METHODS
This is a prospective study conducted for a period of 2 years from August 2013 to July 2015, in the Department of Pathology, Andhra Medical College, Visakhapatnam, India. A total number of 42 cases of ovarian cancers received to the department were included in the study. All non-neoplastic, benign and borderline lesions were excluded. All the relevant clinical details were obtained.
Tissue was subjected to routine processing and sections were stained with hematoxylin and eosin (H&E). The histopathological sections were diagnosed based on WHO classification. 3-4 micron sections were taken from paraffin embedded tissue blocks for immunohistochemistry. Data was analysed statistically using Chi-square test. Positive and negative controls were run with each batch. Positive staining was controlled by positively stained breast carcinoma sections; the negative control was performed on the same tissue without primary antibody. ER and PR are nuclear markers and a positive staining is defined when more than 10% of cells take up the nuclear stain of any intensity. HER2/neu is a cell membrane marker. ER, PR staining was quantified by using Allred score. All the slides were quantified by giving proportional score based on the percentage of cells showing nuclear stain and intensity score based on intensity of staining.
Immunohistochemical assessment of HER2/neu overexpression was graded as per ASCO (American society of clinical oncology)/CAP (college of American Pathologists) 2013 guidelines.
Staging of all the ovarian carcinomas was done according to FIGO (International federation of gynaecology and obstetrics) staging and histological grading was done as per Silverberg's universal grading system.
RESULTS
The commonest clinical presentation in the present study was mass per abdomen (32 cases) followed by pain abdomen (24 cases). Majority of the ovarian cancers (20 cases, 47.6%) were found in the third and fifth decade of life ( Table 1) . Majority of the surface epithelial tumors were of age group above 50 years (44%) and majority of germ cell tumors were below 20years. Half of the metastatic tumors belong to third decade. In the present study, surface epithelial tumors (59.5%) were the commonest followed by germ cell tumors (21.42%) ( Table 2 ). Majority of the ovarian cancers were of stage 3 (35.7%) and grade 2 (57.14%) ( Table 3) . Ascites was associated with ovarian cancer in 42.8% of cases (18 cases) of which majority are of higher grade and higher stage with a "P" value of less than 0.05 which is statistically significant. In the present study, CA-125 levels were available for only 25 cases. Median CA-125 levels were highest in serous (600 IU/ml) and lowest in mucinous carcinoma (60.9 IU/ml). Median CA-125 levels were highest in grade 3 and stage 3 ovarian cancers. ER showed positivity in 9 cases i.e. 21.42% and PR showed positivity in 10 cases i.e. 23.8% of cases. Her2 was weak positive/equivocal in 3 cases i.e. 7.14% (Table 4 ). In the present study, all the 9 ER positive tumors were seen in age group above 40 years and were predominantly of higher stage and higher grade. Association of ER with grade and stage was statistically significant. PR also showed positivity predominantly in age group above 40 years and also in higher grade tumors. Association of Her2/neu with high histological grade was statistically significant (Table 5 ). 
DISCUSSION
In the present study , majority of the ovarian cancers were found in the third and fifth decade of life i.e. 10 cases each, which together accounts for 47.6% of cases. The mean age at presentation was 39.5 years which correlated with Ruchikagarg et al. 5 The youngest patient in our study was of 14 years and the oldest patient was 77 years old. In our study, mass per abdomen was the predominant clinical presentation followed by pain abdomen. In the study conducted by RuchikaGarg et al the commonest presentation was abdominal distension followed by pain abdomen. Four patients were nulliparous and all four had tumor in advanced stage. Family history of ovarian carcinoma was obtained in one case which was a mixed germ cell tumor (yolksac tumor with dysgerminoma).
Malignant surface epithelial tumors were the commonest histological type comprising of 59.5% of all the ovarian carcinomas and serous cystadeno carcinomas being the predominant. Germ cell tumors were the next most common in the present study accounting for 21.42% (9 cases) of all the cancers including 3 cases each of dysgerminoma, yolk sac tumor and mixed germ cell tumors while Shilpa et al had only 3 cases of GCT's. 6 The mixed germ cell tumors in the present study comprising of one case of dysgerminoma with choriocarcinoma, one case of yolk sac tumor with embryonal carcinoma and one case of yolk sac tumor with dysgerminoma.
Metastatic tumors / Krukenberg tumors accounted for 9.52% (4 cases) of ovarian cancers in the present study. Three out of four cases were known to have primary in the stomach. The present study we 6, 7 Majority of the ovarian cancers were found to be of grade 2, which accounts for 57.14% (24 cases) followed by 23.8% (10 cases) of grade 1 and 19.04% (8 cases) of grade 3 tumors. According to Shilpa et al and MT Sylvia et al who followed WHO grading, majority of their cases of ovarian carcinomas were of grade 2 accounting for 45% and 49% respectively in these studies. 6, 7 CA-125 levels were available for 25 cases. With a cutoff point of 35 IU/ml for detecting malignant ovarian tumors, sensitivity was 84% as four out of 25 cases of malignant ovarian tumors had CA-125 levels below 35 IU/ml resulting in false negatives. These cases which had normal CA-125 levels were predominantly early stage tumors. Zorn et al have showed that 7.6% of patients with malignant tumors have normal levels. 8 Median CA-125 levels were raised in all the histological types but were found to be highest in serous cystadeno carcinoma (>600 IU/ml) and malignant Brenner (>600 IU/ml) and lowest in mucinous cystadeno carcinoma (60.9 IU/ml).
Median CA-125 levels were significantly elevated among all grades of the tumors but highest in grade 3 tumors. Similarly median CA-125 levels were highest in stage 3 and stage 4 tumors. Median CA-125 levels were significantly increased in high grade and advanced tumors. These findings of the present study are in concordance with MT Sylvia et al. 7 ER expression was seen in 9 cases accounting for 21.42%. ER showed highest expression in serous cystadeno carcinomas accounting for 66.6% of all ER positive tumors (Figure 1) . ER was positive in 2 cases of endometrioid carcinoma accounting for 22.2% of all ER positive tumors ( Figure 2 ) and single case (100%) of malignant Brenner. ER was negative in all mucinous cystadeno carcinomas, clear cell carcinoma, germ cell tumors, sex cord stromal tumors and metastatic tumors. ER showed higher expression in age group above 40 years, serous carcinomas, higher grade and stage of the tumors and were associated with ascites in majority and had significantly high CA-125 levels thereby suggesting the association of ER expression with advanced disease tumor. The ER positivity in the study was less compared to that of Shilpa et al (32.5%) and MT Sylvia et al (33%). On correlating ER positive tumors with stage and grade, there was statistical significance with a p-value <0.05. Our findings of the study are in concordance with MT Sylvia et al which also reported similar findings for ER expression. In the present study, Her2/neu was weakly positive/ equivocal in only 3 cases accounting for 7.14% which includes one case each of serous cystadenocarcinoma, mucinous cystadenocarcinoma and clear cell carcinoma (Figure 7) . Thus, Her2 expression was seen only in surface epithelial carcinomas. Her2/neu positivity was very less compared to other studies. MT Sylvia et al reported an expression of 21% which is similar to the study done by Mahdi MA with 21.05% positivity. 10 In our study, two of the three cases were above 40 years of age, The expression of steroid hormonal receptors in ovarian cancers paves way for antihormonal therapy/targeted therapy. The role of hormone therapy in the treatment of ovarian cancer is not clear and data on their efficacy and safety in recurrent ovarian cancer have been accumulated through phase II clinical studies. Most of the studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for hormone receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.
CONCLUSION
The expression of steroid receptors paves way for anti hormonal therapy. CA125 levels reflect the tumor bulk and the median levels were higher in tumors with adverse prognostic factors. However, there were inconsistent findings of ER/PR expression and clinicopathological parameters in various studies. Hence, an absolute conclusion could not be derived. We emphasize the need for comprehensive data from more studies that used the same technique (immunohistochemistry), well-marked cut off levels for ER/PR expression and a larger sample size. Such reports would be more informative and are warranted to clarify whether hormone therapy based on hormone receptor status can be an alternative treatment in ovarian carcinoma patients.
